



29 SEPT – 2 OCT 2022  
ICC BELFAST  
NORTHERN IRELAND, UK

# PROGRAMME

DAY 1 Thursday 29 September		Hall 1A
0900 - 1600	Registration   Bag drop <b>Register early:</b> RSV2022 delegates are welcome to join <a href="#">OPTIONS XI DAY 4</a> sessions at the ICC	
1515 - 1600	<b>Poster Setup</b>	
1700 - 1710	Welcome Address: Chair, Prof. Ultan F. Power   Queen's University Belfast	
1710 - 1730	<b>Opening Keynote</b> Early Career Investigator Award Title – tbc Dr Vahid Salimi   Tehran University of Medical Sciences, Iran	
1730 - 1900	<b>SESSION 1 – RSV Molecular Biology</b>	
1730 - 1800	<b>Keynote: Structure and Assembly of RSV</b> Prof. David Bhella   University of Glasgow, UK	
1800 - 1815	<b>RSV Viral Factories are Druggable Multiphasic Biocondensates</b> Marie-Ann Rameix-Welti   Université Paris-Saclay, Université de Versailles, France [ARNI0003]	
1815 - 1830	<b>Elucidating the Role of the Pep27 Fragment in RSV Fusion Protein Function and Stability</b> Hadley Neal   University of Kentucky, USA [ARNI0119]	
1830 - 1845	<b>Respiratory Syncytial Virus NS1 Protein Targets the Transactivator Binding Domain of MED25.</b> Monika Bajorek   INRAE, France [ARNI0009]	
1845 - 1900	<b>Single-molecule Imaging Unravels Real-time Transcription and Replication Dynamics of RSV</b> Dhanushika Ratnayake   Hubrecht Institute, Utrecht, Netherlands [ARNI0136]	
1900 - late	<b>Welcome Reception</b>	
		<b>End of Day 1</b>

**DAY 2**      **Friday 30 September****Hall 1A****0900 - 1030**      **SESSION 2 – RSV Immunology – Pre-Clinical**

**0900 - 0930**      **Keynote: A Novel Microbiota-host Interaction to Explain How Poor Maternal Diet Predisposes to Severe Viral Bronchiolitis**  
A/Prof. Simon Phipps | QIMR Berghofer, QLD, Australia

**0930 - 0945**      **Comparing the Cell-specific Innate Immune response to RSV between preterm and term infants**  
An Yung Ng | Murdoch Children's Research Institute, Royal Children's Hospital, Australia [ARNI0221]

**0945 - 1000**      **Presence of Neutrophils in the Lungs Prior to Infection with Respiratory Viruses Influences Disease Severity in Mice**  
Amber Owen | Imperial College London, UK [ARNI0127]

**1000 - 1015**      **Advanced modeling of RSV Infection in Neonatal Lambs**  
Sarhad Alnajarr | Lambcure LLC, USA [ARNI0029]

**1015 - 1030**      **Trans-epithelial migration is essential for neutrophil activation in the airway during RSV infection**  
Elisabeth Robinson | UCL Great Ormond Street Institute of Child Health, London, UK [ARNI0150]

**1030 - 1100**      **Refreshment break - Posters**

**1100-1230**      **SESSION 3 – RSV Vaccines and Monoclonals**

**1100 - 1130**      **Keynote: Progress in the Prevention of RSV Disease: a Whirlwind Tour**  
Prof. Ruth Karron | Johns Hopkins University, USA

**1130 - 1145**      **Safety and Immunogenicity of mRNA-1345, an mRNA-Based Vaccine Against RSV in Older Adults through 6 Month Follow-up**  
Sonia Stoszek | Moderna, Inc., MA, USA [ARNI0055]

**1145 - 1200**      **NIRSEVIMAB for the Prevention of RSV: Pooled Efficacy from Phase IIB and Phase III Trials in Preterm and Term Infants**  
Eric A.F.Simoës | The Children's Hospital, Aurora, USA [ARNI0139]

**1200 - 1215**      **Long term (2-year) immunogenicity of a combination Ad26.RSV.preF/RSV preF protein vaccine evaluated in a phase 1/2a study**  
Rosemary Bastian Arangassery | Janssen Vaccines and Prevention BV, Netherlands [ARNI0045]

**1215 - 1230**      **Respiratory Syncytial Virus prefusion F (RSVpreF) vaccination: antibody persistence and revaccination**  
Edward Walsh | University of Rochester, NY, USA [ARNI0243]

1230 – 1430	Lunch break   Posters   Industry Symposium sponsored by Sanofi
1430 - 1600	<b>SESSION 4 – RSV Epidemiology and Disease Burden</b>
1430 – 1500	<b>Keynote: An overview of the global burden of RSV</b> Dr Meredith McMorrow   CDC, USA
1500- 1515	<b>Estimates of the National Burden of Respiratory Syncytial Virus in Kenyan Children Aged Under 5 years, 2010-2018</b> Bryan Nyawanda   Kenya Medical Research Institute, Kenya [ARNI0145]
1515 - 1530	<b>Timing of infection with respiratory syncytial virus and risk of childhood asthma</b> Tina Hartert   Vanderbilt University Medical Center, TN, USA [ARNI0172]
1530 - 1545	<b>Hospitalization rates and outcomes for RSV-associated hospitalizations in adults aged 18 years and older in the United States during two respiratory seasons, October 2018 - April 2020</b> Fiona Havers   Centers for Disease Control and Prevention, GA, USA [ARNI0099]
1545 - 1600	<b>Early detection and prediction of respiratory syncytial virus (RSV) outbreaks using wastewater surveillance</b> Danielle Allen   Queen's University Belfast, UK [ARNI0168]
1600 - 1630	Refreshment break - Posters
1630 - 1650	<b>Late Breaker session</b>
1630 - 1640	<b>PK, SNA, and Efficacy to Prevent RSV MALRI from a Phase 1b/2a Study of Monoclonal Antibody Clesrovimab (MK-1654) in Infants</b> Andrew Lee   Merck & Co Inc., USA [ARNI0268]
1640 - 1650	<b>Nirsevimab for the prevention of RSV disease in healthy late-preterm and term infants: follow-up through second RSV season</b> Ron Dagan   Ben Gurion University, Beer Sheva Israel [ARNI0273]
1650 - 1800	<b>SESSION 5 – Public Engagement and Question Time</b>
1800 - 2000	Poster Session   Wine Reception
<b>End of Day 2</b>	

**DAY 3 Saturday 1 October****Hall 1A****0900 - 1030****SESSION 6 – RSV Antivirals and Therapeutics**

0900 – 0930

**Therapeutic Targeting of the RSV Polymerase Complex****Keynote:** Prof Richard Plemper | Georgia State University, Atlanta, USA

0930 - 0945

**A Phase 3 Pivotal Study of Efficacy and Safety of Oral Ziresovir in RSV-Infected Hospitalized Infants**

Jim Wu | Shanghai Ark Biopharmaceutical, China

[ARNI0072]

0945 - 1000

**EDP-323, a Novel L-Protein Inhibitor, for the Treatment of Respiratory Syncytial Virus**

Micheal Rhodin | Enanta Pharmaceuticals, MA, USA

[ARNI0028]

1000 - 1015

**Immunomodulation Strategy Against Respiratory Syncytial Virus Infection by Using Lung Primocolonizing Bacteria**

Claire Chottin | INRAE, France

[ARNI0242]

1015 - 1030

**Repurposing Screen Identifies Ionafarnib as RSV Fusion Protein Inhibitor**

Xiaoyu Zhang | Institute for Experimental Virology, Twincore, Hannover, Germany

[ARNI0122]

1030 - 1100

**Refreshment break - Posters****1100 - 1230****SESSION 7 – RSV Pathogenesis and Immunity in Humans**

1100 – 1130

**Older Age and its Impact on Infection in Adults after Human RSV Challenge****Keynote:** Prof Chris Chiu | Imperial College London, UK

1130 - 1145

**Severity-Associated Transcriptional Signatures in the Respiratory Mucosa during Human Paediatric RSV Infection**

Megan Barnes | Imperial College London, UK

[ARNI0087]

1145 - 1200

**Assessment of Pediatric Lung Respiratory Syncytial Virus Infection at the Single Cell Level**

Thomas Mariani | University of Rochester, NY, USA

[ARNI0178]

1200 - 1215

**Differential responses of paediatric airway epithelium from wheezers and non-wheezers to RSV and/or aeroallergens**

Sheerian Manzoor | Queen's University Belfast, UK

[ARNI0084]

1215 - 1230

**Sex-Dependent Enhancement of Respiratory Syncytial Virus Infection by Toll-Like Receptor 7**

Ryley McClelland | University of Alberta, Canada

[ARNI0190]

1230 - 1430

**Lunch**

1300 - 1400	<p><b>Industry symposium sponsored by GlaxoSmithKline Biologicals SA</b>  <b>Gaining clarity: the factors that increase risk of viral respiratory disease in adults</b></p> <p>1300-1305 <b>Welcome &amp; Introductions</b> – Peter Openshaw   Imperial College London, UK  1305-1315 <b>Burden of Respiratory Disease in High-Risk Adult Populations</b>  Ann Falsey   University of Rochester School of Medicine, New York, USA  1315-1330 <b>Immune Mechanisms Underlying Risk of Infectious Disease in Adults</b>  Steven Varga   University of Iowa, Iowa City, USA  1330-1345 <b>Respiratory Disease Pathogenesis in Adults</b>  Peter Openshaw   Imperial College London, UK  1345-1355 <b>Audience Q&amp;A</b> – all speakers  1355-1400 <b>Closing remarks</b> - Peter Openshaw   Imperial College London, UK</p>
1430 - 1630	<p><b>SESSION 8 – RSV Co-infections with Other Viruses and/or Bacteria</b></p>
1430 - 1500	<p><b>Keynote:</b> Dr Natasha Halasa   Vanderbilt University Medical Center, USA</p>
1500 - 1515	<p><b>In Vitro Coinfection by Respiratory Syncytial Virus and Influenza A Virus Generates Hybrid Virions with Altered Structure and Tropism</b>  Joanne Haney   MRC-University of Glasgow Centre for Virus Research, UK [ARNI0248]</p>
1515 - 1530	<p><b>Streptococcus Pneumoniae Carriage Density and Associated Respiratory Virus Coinfections in a Congregate Shelter Population in King County, WA</b>  Julia Rogers   University of Washington, USA [ARNI0189]</p>
1530 - 1545	<p><b>Viral Infections and Co-infections Among American Indian and Alaska Native Children with Acute Respiratory Illness, 2019-2022</b>  Rachel Hartman   Johns Hopkins University, USA [ARNI0232]</p>
1545 - 1600	<p><b>Strong Remodeling of RSV-induced Transcriptional Signature in the Early Stages of Bacterial Superinfection in Human Airway Epithelium</b>  Justine Oliva   CIRI (Centre International de Recherche en Infectiologie), France [ARNI0135]</p>
1600 - 1630	<p><b>Refreshment break   Posters</b></p>
1630 - 1730	<p><b>Chanock Lecture – Prof. Larry Anderson, Emory University, USA</b>  <b>RSV Then, Now and Tomorrow, One View</b></p>
1730 - 1815	<p><b>Free time</b></p>
1815 - 1830	<p><i>bus transportation from ICC to Conference Social Event</i></p>
1830 - late	<p><b>Gala Evening at the Titanic Centre</b>  <b>Titanic Centre Tour, Wine Reception &amp; Gala Dinner</b> <span style="float: right;"><b>End of Day 3</b></span></p>

**0930 - 1100      SESSION 9 – HMPV and Other Respiratory Viruses**

0930 - 1000	<b>Human Metapneumovirus Replication and Spread</b> <b>Keynote:</b> Prof. Rebecca Dutch   University of Kentucky College of Medicine, USA
1000 - 1015	Human metapneumovirus lacking M2-2 protein expression accumulates defective interfering particles and hypermutated genomes that induce type-I interferon production upon infection. Kevin Groen   Erasmus MC, Netherlands [ARNI0180]
1015 - 1030	Investigating The Role of HIF-1a in hMPV and RSV Infections Dorothea Morris   University of Texas Medical Branch, USA [ARNI0048]
1030 - 1045	Cross-Protective Antibodies Against Common Endemic Respiratory Viruses Jim Boonyaratanakornkit   Fred Hutchinson Cancer Center, WA, USA [ARNI0096]
1045 - 1100	Immunocompromised Cotton Rat Model of Human Metapneumovirus (hMPV) Infection Marina Boukhvalova   Sigmovir Biosystems, Inc., USA [ARNI0174]

**1100 – 1130      Refreshment break | Posters**

**1130 - 1300      SESSION 10 – Big Data and RSV**

1130 - 1200	<b>Using Data to Guide Policy – From Community Transmission to Vaccine Implementation</b> <b>Keynote:</b> Prof. Cheryl Cohen   University of Witwatersrand & Co-head NICD, S.Africa
1200 - 1215	Examining the Relationship Between Respiratory Syncytial Virus, Influenza, and Rotavirus Seasons' Timing and Severity, and Infant Age at Viral Seasons' Peaks, with Subsequent Childhood Asthma Michelle Dimitris   Children's Hospital of Eastern Ontario, Canada [ARNI0056]
1215 - 1230	A large-scale multi-national prospective observational cohort study documenting the summer 2021 RSV epidemic in the United Kingdom and Ireland Thomas Williams   University of Edinburgh, UK [ARNI0059]
	<b>Machine Learning in asthma: Uncovering the Link with RSV Bronchiolitis</b> <b>Keynote:</b> Prof. Adnan Custovic   Imperial College London, UK

**1300 - 1500      Lunch**

<p>1330 - 1430</p>	<p><b>Industry symposium sponsored by AstraZeneca</b>  <b>Understanding the Heritage of RSV Immunoprophylaxis to Inform the Care of Our Vulnerable Patients</b>  <b>Prof. Sánchez Luna   Paediatrics Dept., Hospital General Universitario 'Gregorio Marañón' &amp; Medical Director Neonatology Division NICU</b></p> <p>1330-1410  Presentation overview:</p> <ul style="list-style-type: none"> <li>• Current status of RSV infection, epidemiology and unmet needs</li> <li>• Long-term sequelae of early lung insults</li> <li>• Current management guidelines and recommendations for the prevention of RSV infections</li> <li>• The concept of RSV immunoprophylaxis - recommended approach for prevention and treatment of RSV-related clinical outcomes</li> </ul> <p>1410-1430</p> <ul style="list-style-type: none"> <li>• Q&amp;A session</li> </ul>
<p>1500 - 1630</p>	<p><b>SESSION 11 – The BIG DEBATE</b>  <i>Our rudimentary understanding of RSV pathogenesis in humans remains a major block to developing RSV vaccines and antivirals</i></p>
<p>1630 -&gt;</p>	<p><b>Closing Remarks</b></p>
<p><b>End of Day 4</b></p>	